Latest / Early Edition with Ryan Bridge / Neil Woodhams: Multiple Sclerosis New Zealand President on their call to change how Pharmac funds drugs in New Zealand

Transcript

Neil Woodhams: Multiple Sclerosis New Zealand President on their call to change how Pharmac funds drugs in New Zealand · Early Edition with Ryan Bridge

• 0:00
  Speaker 1: Are there are calls for FARMAC to change up the
• 0:01
  Speaker 1: way it funds drugs are report commissioned by Multiple Sclerosis
• 0:05
  Speaker 1: New Zealand says it's time to base funding decisions not
• 0:08
  Speaker 1: just on the cost of the medical device, but on
• 0:11
  Speaker 1: the impact we'll have on the health system and society
• 0:13
  Speaker 1: as a whole. The cost benefit model has been widely
• 0:16
  Speaker 1: used overseas and was recommended by the Treasury in twenty fifteen.
• 0:20
  Speaker 1: Neil Woodhams is the Multiple Sclerosis New Zealand President. He's
• 0:23
  Speaker 1: with me this morning. Neil, Good morning to you.
• 0:25
  Speaker 2: Good morning Ryan, how are you well?
• 0:27
  Speaker 1: Thank you. My first question is has this not changed already?
• 0:30
  Speaker 1: David Seymour gave a directive, did he not to Farmac
• 0:34
  Speaker 1: to do something like this?
• 0:36
  Speaker 2: Yes, we are hopeful as this changed. We actually started
• 0:41
  Speaker 2: this report last year and it's the first detailed, evidently
• 0:49
  Speaker 2: based report on the subject. We think it supports David
• 0:54
  Speaker 2: Seymour's position, but we also think it's worthwhile demonstrating execs
• 1:00
  Speaker 2: what those costs are and how significant they are.
• 1:04
  Speaker 1: Can you give us one example of a medicine that
• 1:06
  Speaker 1: we don't currently fund, you know, using the old model
• 1:11
  Speaker 1: versus your new one.
• 1:13
  Speaker 2: Well, the medicine that we use in this case is
• 1:16
  Speaker 2: a drug called ocalism ab, which has been approved for
• 1:22
  Speaker 2: relapsing remitting MS, but not for primary progressive MS until
• 1:27
  Speaker 2: just very recently. It took us about I suppose eight
• 1:31
  Speaker 2: years to get that drug approved, and so we've based
• 1:38
  Speaker 2: the report, or Richard Milners based the report on the
• 1:42
  Speaker 2: modeling that was done for OSM. But the model that
• 1:47
  Speaker 2: he's used is applicable to any drug in a similar situation.
• 1:53
  Speaker 1: It's basically saying there are wider benefits to society, to
• 1:57
  Speaker 1: the health system, etc. From using these drugs other than
• 2:00
  Speaker 1: it might save one, two, three lives whatever.
• 2:04
  Speaker 2: That's absolutely right. I mean there are significant costs to
• 2:08
  Speaker 2: the government in a disease like multiple sclerosis that farmic
• 2:16
  Speaker 2: don't take into account. For example, this cost to social
• 2:22
  Speaker 2: welfare when people stop working and go on to an
• 2:25
  Speaker 2: unemployment benefit or a disability benefit. But there's also very
• 2:29
  Speaker 2: substantial cost to the family and to the individual. People
• 2:33
  Speaker 2: with MS may well stop work fifteen twenty years before
• 2:40
  Speaker 2: they would be due to retire, and so there's the
• 2:43
  Speaker 2: whole impact economic impact of the family of a loss
• 2:47
  Speaker 2: of an income and then on retirement, can we save
• 2:50
  Speaker 2: for etc.
• 2:51
  Speaker 1: Etc. It's interesting, isn't it. I mean something you would
• 2:54
  Speaker 1: have thought obviously Treasury recommended it in twenty fifteen. It's
• 2:56
  Speaker 1: something you would have thought that a government would be
• 2:59
  Speaker 1: looking at doing, or a lens through which they would
• 3:02
  Speaker 1: look at funding. Anyway, Neil, thank you for that. New
• 3:04
  Speaker 1: Wadham's the multiple Scleritist New Zealand President.
• 3:08
  Speaker 2: For more from early edition with Ryan Bridge. Listen live
• 3:11
  Speaker 2: to news Talks. It'd be from five a m. Week days,
• 3:14
  Speaker 2: or follow the podcast on iHeartRadio